Skip to main content
Equibles
GUTS logo

GUTS · Fractyl Health, Inc. · Metrics

Track GUTS — free

Use GUTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GUTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.08 -0.05 (-4.42%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”
View the 10-Q filed Aug 10, 2026
Market Cap
$14.33M
Shares
13.26M
Volume · Oct 23 437.9K Avg daily vol (15 sessions) 1.36M

GUTS metrics

50 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.08
Market cap
$14.33M

Price action

20 metrics
Price change (1W)
-30.3%
Price change (30D)
-76.3%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
8.1
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
13.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
154.0×
reciprocal yield 0.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-737.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-16

Profitability

9 metrics
Gross margin
46.2%
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$43,000
Operating profit (TTM)
−$85.89M
Net income (TTM)
−$105.65M
Trailing 12 months
Diluted EPS (TTM)
$-10.80
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.03
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
$-19.97
Capital expenditures per diluted share (TTM)
$0.19
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.74

Growth

11 metrics
Revenue growth YoY
-57.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$93,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+223.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-128.9%
Debt / equity
—
Current ratio
3.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$47.14M
Latest balance sheet
Cash & equivalents
$47.14M
Total assets
$81.98M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$82.43M
Capital expenditures (TTM)
$557,000
R&D (TTM)
$63.36M
SG&A (TTM)
$22.53M
Stock compensation (TTM)
$8.52M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
77
13F filer change QoQ
-7
Institutional ownership
44.5%
Conviction holders (share of 13F filers)
3.9%
Crowding (high-turnover and private-fund holders)
28.2%
Private-fund adviser ownership
26.8%
Active holders' share change QoQ
-2.5%
Holder tenure
6.2
Price vs estimated holder cost
-69.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.5%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
31 / 100

Insider activity

2 metrics
Net insider buying (90D)
$39,903
Insider-sentiment score
79 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1572616 CUSIP 35168W103 13F (30d) 6 filings 6 filers Visit website Investor relations